Glaukos Corporation (NYSE:GKOS – Get Free Report) COO Joseph Gilliam sold 44,917 shares of the stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $246.32, for a total transaction of $11,063,955.44. Following the completion of the transaction, the chief operating officer directly owned 71,602 shares of the company’s stock, valued at $17,637,004.64. This trade represents a 38.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Glaukos Price Performance
Shares of Glaukos stock traded down $0.69 during midday trading on Monday, hitting $245.03. 848,336 shares of the company were exchanged, compared to its average volume of 1,924,346. The firm has a 50 day simple moving average of $185.95 and a 200-day simple moving average of $147.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. Glaukos Corporation has a 52 week low of $87.32 and a 52 week high of $255.18.
Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million for the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business’s revenue was up 58.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) earnings per share. As a group, sell-side analysts anticipate that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on Glaukos
Institutional Investors Weigh In On Glaukos
Hedge funds and other institutional investors have recently made changes to their positions in the company. Soleus Capital Management L.P. bought a new position in Glaukos in the third quarter valued at about $4,195,000. Cetera Investment Advisers increased its position in Glaukos by 6.1% in the third quarter. Cetera Investment Advisers now owns 3,402 shares of the medical instruments supplier’s stock worth $559,000 after purchasing an additional 197 shares during the period. Entropy Technologies LP acquired a new stake in Glaukos in the third quarter worth about $402,000. Jump Financial LLC bought a new stake in Glaukos during the 3rd quarter worth about $2,014,000. Finally, Pathstone Holdings LLC raised its holdings in Glaukos by 9.0% during the 3rd quarter. Pathstone Holdings LLC now owns 17,676 shares of the medical instruments supplier’s stock worth $2,902,000 after purchasing an additional 1,462 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Recommended Stories
- Five stocks we like better than Glaukos
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
